NCT06926998View on ClinicalTrials.gov

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2027

Conditions
Gynecological Malignancies
Interventions
DRUG

9MW2821+other anticancer therapy

Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT06926998 - 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors | Biotech Hunter | Biotech Hunter